Recruiting studies: Chronic Phase Chronic Myelogenous Leukemia Bcr Abl1 Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533 Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
NA · 1 location(s) · Centre Hospitalier Henri Duffaut - Avignon · NCT06082804 PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2 · 11 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06409936 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921 Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803 MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid L
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05007873 Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
Phase 1 · 1 location(s) · Mendus · NCT07651878 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090 A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chr
Phase N/A · 54 location(s) · Novartis Pharmaceuticals · NCT07549516 Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295 Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resis
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01746836 Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Phase N/A · 1 location(s) · University of California, Irvine · NCT06229860 A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Out
Phase N/A · 17 location(s) · Novartis Pharmaceuticals · NCT07091019 Asciminib Roll-over Study
Phase 4 · 85 location(s) · Novartis Pharmaceuticals · NCT04877522 Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074 Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825 Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leu
Phase 2 · 4 location(s) · Medical College of Wisconsin · NCT04838041 Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741 ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Phase 1 · 4 location(s) · Enliven Therapeutics · NCT06787144 A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participa
Phase 1/Phase 2 · 54 location(s) · Terns, Inc. · NCT06163430 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643 A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Phase 1 · 45 location(s) · Enliven Therapeutics · NCT05304377 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06059391 RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Phase N/A · 4 location(s) · Novartis Pharmaceuticals · NCT06684964 Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991 TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Phase 2 · 1 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06453902 TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888 Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03589729 Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi
Phase 2 · 6 location(s) · Novartis Pharmaceuticals · NCT06514534

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.